IL15 and neoplasm: Intriguingly, in mice treated with IL13-Rα2.IL-15-CAR T cells, tumors recurred at late time points and the majority of relapsed tumors no longer expressed IL-13Rα2, implicating antigen loss as a tumor escape mechanism in this model.